Business Wire

AVANZANITE-BIOSCIENCE

27.8.2024 07:01:26 CEST | Business Wire | Press release

Share
Avanzanite Bioscience Reports European Commission's Authorisation of Orphan Medicinal Product AKANTIOR®

Avanzanite Bioscience B.V., a commercial-stage specialty pharmaceutical company, focused on bringing novel medicines for rare diseases to market, announced today that the European Commission (EC) granted marketing authorisation of AKANTIOR® (polihexanide) for the treatment of acanthamoeba keratitis (AK) in adults and children from 12 years of age. The formal approval by the EC follows previously reported positive opinion of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) as well as subsequent positive recommendation of the EMA Committee for Orphan Medicinal Products (COMP). Following more than 16 years of research & development (R&D), AKANTIOR is the first and only authorised medicinal product for the treatment of AK globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240826744342/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adam Plich, Founder & CEO of Avanzanite Bioscience (Photo: Business Wire)

“Our studies have shown that with AKANTIOR, when used as monotherapy with the treatment delivery protocol established for use in the trial, medical cure rates of over 85% can be achieved. As the first authorised drug, I expect this to become the standard of care for this severe disease,” stated John Dart, Principal Investigator of the pivotal phase III ODAK trial, and Professor at the Moorfields Eye Hospital and the University College London Institute of Ophthalmology. “AKANTIOR can be expected to improve the cure rate without surgery, reducing both the high rates of morbidity – principally anxiety, pain, time off normal activities, time to cure – and blindness rates associated with current unlicensed, often compounded, combination therapies.”

In March 2024, results of the 135-patient, phase III, pivotal Orphan Drug for Acanthamoeba Keratitis (ODAK) trial, were published in Ophthalmology, demonstrating AKANTIOR’s absolute efficacy and safety. The trial showed that 84.8% of patients receiving AKANTIOR were cured. Furthermore, 66.7% of patients treated with AKANTIOR achieved full vision restoration with no patients resorting to optical cornea transplant. Only 7.5% of AKANTIOR-treated patients required a therapeutic cornea transplant.

“As an acanthamoeba keratitis (AK) Warrior, I am optimistic that AKANTIOR will have a significant and positive impact on AK patients,” commented Juliette Vila Sinclair Spence, a rare disease patient advocate and the Chairwoman and Founder of AK Eye Foundation – the first global foundation dedicated exclusively to this condition. “When I was diagnosed with AK, for me, there were no authorised drugs or standardised treatment protocols like AKANTIOR available. I had to rely on various compounded or off-label eye drops without a validated protocol. This approval has reignited my passion and commitment to increasing awareness about this rare eye disease.”

Acanthamoeba keratitis (AK) is a rare, severe, and progressive parasitic corneal infection caused by Acanthamoeba, a free-living amoeba. Urgent medical intervention is necessary as the disease leads to blindness and eye loss. AK often requires single or multiple cornea transplant procedures with comparably low graft survival rates. Patients report unbearable pain and extreme light sensitivity and can rarely work or lead normal lives until symptoms resolve, leaving patients with trauma for life. AK primarily affects contact lens wearers and is responsible for 50% of blindness cases in this demographic. In the absence of anti-amoebal treatment, 80.4% of patients require surgery, such as therapeutic cornea transplant, or eye removal in a historical cohort of 56 patients.

“No one fighting such a devastating rare disease should be left behind. This marketing authorisation is the beginning of a new chapter for the treatment of acanthamoeba keratitis (AK) and a monumental victory for AK patients in Europe,” stated Avanzanite’s Founder & CEO, Adam Plich. “We are grateful to our R&D partners at SIFI, the healthcare professionals, as well as the patients and their families who participated in the trials, for the years of dedication and hard work that made this day possible.”

To date, AKANTIOR has been provided to more than 200 patients across 12 countries through a pre-authorisation distribution program. “At Avanzanite, we are committed to supporting broad access to our innovative therapies and look forward to collaborating with local health authorities in 26 European countries to secure sustainable access agreements so we can save the eyes of as many eligible patients as possible,” Plich concluded.

Avanzanite secured exclusive rights to commercialise AKANTIOR in 26 countries across the European Economic Area and Switzerland through a license and supply agreement with SIFI, a leading international ophthalmic company headquartered in Italy. AKANTIOR is the second rare disease medicine commercialised by Avanzanite, expanding both the company’s portfolio and geographical footprint, in support of the ambition to become a global rare disease company.

ABOUT AKANTIOR®: AKANTIOR (polihexanide) is the first European Commission-approved medicinal product for AK. It is an anti-amoebic polymer granted Orphan Drug Designation (ODD) by the European Medicines Agency ("EMA") and Food and Drug Administration ("FDA"). It acts on both the trophozoites and cysts of the protozoan Acanthamoeba. It is formulated at a unique high 0.8 mg/ml (0.08%) dose strength administered through a validated and standardised, day-only protocol as monotherapy eye drops in single-dose containers. Polihexanide is also being developed for the treatment of fungal keratitis for which it has ODD from both FDA and EMA.

ABOUT AVANZANITE BIOSCIENCE: We believe all patients should benefit from novel orphan or niche medicines regardless of where they live. Our vision is that no one is left behind when facing a debilitating rare disease. We also believe the people who have dedicated their careers to the research & development of novel orphan or niche medicines, deserve to witness how their tremendous efforts impact patients’ lives – the work of these heroes should not lie in vain. We make this happen by acquiring, licensing, or distributing approved or late-stage medicines for rare diseases, unlocking their potential, and commercialising them even where nobody else will. Founded in 2022, Avanzanite is headquartered in Amsterdam, the Netherlands, with commercial infrastructure and technical operations across Europe. Visit www.avanzanite.com for additional information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240826744342/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns18.11.2026 09:01:00 CET | Press release

Organizations with embedded network resilience report outage costs $6 million lower, Opengear research finds Nearly three in four organizations (72%) have delayed, scaled back or paused an AI or edge project in the past 12 months over concerns about network resilience, according to new research from Opengear, a Digi International company (NASDAQ: DGII) (www.digi.com). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118888190/en/ 72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns The same research shows how the best-prepared organizations fare. Organizations with embedded network resilience, meaning they can reach and recover critical infrastructure when the primary network is down, reported estimated average outage costs $6 million lower over the past 12 months than organizations with less developed resilience capabilities ($12.4 million versus $18.8 million). The advanta

SWISSto12 Selects DLR GSOC as Flight Dynamics Software Partner to Support Upcoming HummingSat Satellite Missions18.11.2026 09:00:00 CET | Press release

Agreement underscores SWISSto12’s expanding relationship with key players in Germany’s space ecosystem SWISSto12, one of the world’s fastest-growing satellite and aerospace companies, today announced it has contracted the German Aerospace Center (DLR) to serve as the company’s primary flight dynamics software provider across its upcoming HummingSat GEO satellite missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118073472/en/ SWISSto12 has selected DLR’s GSOC as its primary flight dynamics software provider for upcoming HummingSat GEO satellite missions. Under this agreement, GSOC will deliver capabilities that span orbit determination, propagation, manoeuvre planning and calibration, orbit events, antenna pointing, and long-term mission analysis. The collaboration is designed to standardise flight dynamics across SWISSto12 programmes, using a heritage European solution integrated into the company’s ground segment a

Abbove Brings European Wealth Planning Into the AI Era18.11.2026 08:05:00 CET | Press release

With the new Abbove MCP connector, advisors can now securely connect their AI tools to their clients’wealth data held in Abbove. Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors

Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 06:00:00 CET | Press release

The AI adoption race is giving way to a bigger divide: firms that redesign work and those that fall behind Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global re

Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 05:30:00 CET | Press release

Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem.Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is alr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye